The Role of Absorption, Distribution, Metabolism, Excretion and Toxicity in Drug Discovery
The DOI matches its Crossref record.
Abstract
Major reasons preventing many early candidates reaching market are the inappropriate ADME (absorption, distribution, metabolism and excretion) properties and drug-induced toxicity. From a commercial perspective, it is desirable that poorly behaved compounds are removed early in the discovery phase rather than during the more costly drug development phases. As a consequence, over the past decade, ADME and toxicity (ADMET) screening studies have been incorporated earlier in the drug discovery phase. The intent of this review is to introduce the desirable attributes of a new chemical entity (NCE) to the medicinal chemist from an ADMET perspective. Fundamental concepts, key tools, reagents and experimental approaches used by the drug metabolism scientist to aid a modern project team in predicting human pharmacokinetics and assessing the "drug-like" molecule are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00104 · Cited by 5,716
The application of in silico drug-likeness predictions in pharmaceutical research
Tian, S., Wang, J., Li, Y., Li, D., Xu, L., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.009 · Cited by 498
Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.554 · Cited by 497
The role of the medicinal chemist in drug discovery — then and now
Lombardino, J. G., & Lowe, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1523 · Cited by 452
Computational Approaches in Preclinical Studies on Drug Discovery and Development
Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., Liang, X., Tan, M., & Huang, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00726 · Cited by 446
Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction
Myung, Y., de Sá, A. G. C., & Ascher, D. B. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae254 · Cited by 337
Three-dimensional cellular microarray for high-throughput toxicology assays
Lee, M.-Y., Kumar, R. A., Sukumaran, S. M., Hogg, M. G., Clark, D. S., & Dordick, J. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708756105 · Cited by 314
Su, R., Wu, H., Xu, B., Liu, X., & Wei, L. (2019) · IEEE/ACM Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2018.2858756 · Cited by 134
“However, almost 60 percent of the drugs failed because of the poor absorption, distribution, metabolism, excretion, and toxicity (ADMET) of the compound [2].”
Background(2004) · PubMed · Cited by 66
Nanoparticles guided drug delivery and imaging in gastric cancer
Nagaraju, G. P., Srivani, G., Dariya, B., Chalikonda, G., Farran, B., Behera, S. K., Alam, A., & Kamal, M. A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.006 · Cited by 62
Christopher, L. J., Cui, D., Li, W., Barros, A., Arora, V. K., Zhang, H., Wang, L., Zhang, D., Manning, J. A., He, K., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018234 · Cited by 40
“Metabolism studies of drug candidates have become an integral part of the drug discovery and development process (Lin et al., 2003; Roberts, 2003).”
BackgroundMulti-organ model assessment of neurotoxicity following exposure of liver spheroids to drugs
Wu, W., Anas, F., Koc, B., Tian, L., Hasselkus, R., Rezania, D., Sharareh, S., Farberov, L., Zlotnik, D., Alon, A., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118021 · Cited by 5
Metadata
- Authors
- Lin, J., Sahakian, D., de Morais, S., Xu, J., Polzer, R., & Winter, S.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-05-01
- Volume
- 3
- Issue
- 10
- Pages
- 1125-1154
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W1982694126
- Cited by
- 327
- References
- 0
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.